134 related articles for article (PubMed ID: 31129148)
1. RETRACTED: IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas.
Mihajluk K; Simms C; Reay M; Madureira PA; Howarth A; Murray P; Nasser S; Duckworth CA; Pritchard DM; Pilkington GJ; Hill R
Cancer Lett; 2019 Aug; 458():29-38. PubMed ID: 31129148
[TBL] [Abstract][Full Text] [Related]
2. Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling.
Oh H; Hwang I; Jang JY; Wu L; Cao D; Yao J; Ying H; Li JY; Yao Y; Hu B; Wang Q; Zheng H; Paik J
Cancer Res; 2021 Mar; 81(6):1528-1539. PubMed ID: 33509942
[TBL] [Abstract][Full Text] [Related]
3. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.
Murakami A; Takahashi F; Nurwidya F; Kobayashi I; Minakata K; Hashimoto M; Nara T; Kato M; Tajima K; Shimada N; Iwakami S; Moriyama M; Moriyama H; Koizumi F; Takahashi K
PLoS One; 2014; 9(1):e86459. PubMed ID: 24489728
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
6. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial.
Narita Y; Muragaki Y; Kagawa N; Asai K; Nagane M; Matsuda M; Ueki K; Kuroda J; Date I; Kobayashi H; Kumabe T; Beppu T; Kanamori M; Kasai S; Nishimura Y; Xiong H; Ocampo C; Yamada M; Mishima K
Cancer Sci; 2021 Dec; 112(12):5020-5033. PubMed ID: 34609773
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse.
Shaw PH; Maughan TS; Clarke AR
Br J Cancer; 2011 Aug; 105(5):649-57. PubMed ID: 21811251
[TBL] [Abstract][Full Text] [Related]
9. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.
Yao TW; Zhang J; Prados M; Weiss WA; James CD; Nicolaides T
Oncotarget; 2015 Sep; 6(26):21993-2005. PubMed ID: 26023796
[TBL] [Abstract][Full Text] [Related]
10. Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2.
Zhang X; Liu X; Zhou W; Yang M; Ding Y; Wang Q; Hu R
Cell Death Dis; 2018 Feb; 9(2):190. PubMed ID: 29416017
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y
Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182
[TBL] [Abstract][Full Text] [Related]
12. mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
Garros-Regulez L; Aldaz P; Arrizabalaga O; Moncho-Amor V; Carrasco-Garcia E; Manterola L; Moreno-Cugnon L; Barrena C; Villanua J; Ruiz I; Pollard S; Lovell-Badge R; Sampron N; Garcia I; Matheu A
Expert Opin Ther Targets; 2016; 20(4):393-405. PubMed ID: 26878385
[TBL] [Abstract][Full Text] [Related]
13. AS602801 sensitizes glioma cells to temozolomide and vincristine by blocking gap junction communication between glioma cells and astrocytes.
Zhang S; Gong Y; Wang H; Li Z; Huang Y; Fu X; Xiang P; Fan T
J Cell Mol Med; 2021 Apr; 25(8):4062-4072. PubMed ID: 33609076
[TBL] [Abstract][Full Text] [Related]
14. Retraction notice to " IP1867B suppresses the Insulin-like Growth Factor 1 Receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas" [Canc. Lett., 458 (2019) pages 29-38].
Mihajluk K; Simms C; Reay M; Madureira PA; Howarth A; Murray P; Nasser S; Duckworth CA; Pritchard DM; Pilkington GJ; Hill R
Cancer Lett; 2021 Jun; 507():39. PubMed ID: 33743517
[No Abstract] [Full Text] [Related]
15. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
16. Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models.
Longo SL; Padalino DJ; McGillis S; Petersen K; Schirok H; Politz O; Canute GW; Post DE
Invest New Drugs; 2012 Dec; 30(6):2161-72. PubMed ID: 22203214
[TBL] [Abstract][Full Text] [Related]
17. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
Hu YH; Jiao BH; Wang CY; Wu JL
CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245
[TBL] [Abstract][Full Text] [Related]
18. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
19. Corrigendum to "IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas." [Cancer Lett. 458C (2019) 29-38].
Mihajluk K; Simms C; Reay M; Madureira PA; Howarth A; Murray P; Nasser S; Duckworth CA; Pritchard DM; Pilkington GJ; Hill R
Cancer Lett; 2020 Jan; 469():524-525. PubMed ID: 31604579
[No Abstract] [Full Text] [Related]
20. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
